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Abstract
Epidemiological and genetic studies suggest that schizophrenia and autism may share genetic links. Besides common single
nucleotide polymorphisms, recent data suggest that some rare copy number variants (CNVs) are risk factors for both
disorders. Because we have previously found that schizophrenia and psychosis in Alzheimer’s disease (AD+P) share some
genetic risk, we investigated whether CNVs reported in schizophrenia and autism are also linked to AD+P. We searched for
CNVs associated with AD+P in 7 recurrent CNV regions that have been previously identified across autism and
schizophrenia, using the Illumina HumanOmni1-Quad BeadChip. A chromosome 16p11.2 duplication CNV (chr16:
29,554,843-30,105,652) was identified in 2 of 440 AD+P subjects, but not in 136 AD subjects without psychosis, or in 593 AD
subjects with intermediate psychosis status, or in 855 non-AD individuals. The frequency of this duplication CNV in AD+P
(0.46%) was similar to that reported previously in schizophrenia (0.46%). This duplication CNV was further validated using
the NanoString nCounter CNV Custom CodeSets. The 16p11.2 duplication has been associated with developmental delay,
intellectual disability, behavioral problems, autism, schizophrenia (SCZ), and bipolar disorder. These two AD+P patients had
no personal of, nor any identified family history of, SCZ, bipolar disorder and autism. To the best of our knowledge, our case
report is the first suggestion that 16p11.2 duplication is also linked to AD+P. Although rare, this CNV may have an important
role in the development of psychosis.
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Introduction
About 40–60% of patients with late-onset Alzheimer’s disease
(AD), defined by an onset after age 60 years, develop psychosis
(AD+P) [1,2]. The estimated heritability of AD+P is about 61%
[3]. Recent large scale genome-wide association study (GWAS) of
Alzheimer’s disease with psychotic symptoms [3] found several
single nucleotide polymorphisms (SNPs) that were tentatively
associated with AD+P when compared to AD-P, but none of them
were genome-wide significant. Some of these associations were
overlapped with other psychiatric disorders with psychotic features
such as schizophrenia (SCZ). Several other studies also reported
some susceptibility loci and candidate genes for AD+P which
increased the risk of schizophrenia (SCZ) and other psychiatric
disorders, although the specific genetic determinants remain to be
identified [1,4–6].
One type of genetic variant that has been of great interest in the
field of psychiatric disorders in the past few years is DNA copy
number [7–10]. Since GWAS did not identify SNPs that can
explain the high heritability of AD+P, rare structural variation
such as CNVs may play a role and account for missing heritability.
Recent studies have shown that autism and SCZ share several rare
copy number variants (CNVs) [10,11]. Some of these CNVs are
also shared with various intellectual disability syndromes [12].
Moreno-De-Luca et al [13] summarized CNV studies in autism
and SCZ, and reported 7 recurrent CNVs across autism and SCZ,
which included a deletion on chromosome 1q21.1 (position in
human genome build 36/hg18: 144,963,732-145,864,377), a
deletion on chromosome 3q29 (197,244,288-198,830,238), a
deletion on chromosome 15q13.3 (28,698,632-30,234,007), a
duplication on chromosome 16p11.2 (29,557,553-30,107,434), a
duplication on chromosome 16p13.11 (15,421,876-16,200,195), a
deletion on chromosome 17q12 (31,893,783-33,277,865) and a
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deletion on chromosome 22q11.2 (17,412,646-19,797,314). These
7 CNVs share two features: large size and rare frequency. Each of
these CNV regions contains tens to hundreds of genes and their
frequencies in cases and controls were about 0.5%, and 0.05%,
respectively. We designed this study to examine whether AD+P
shares risk CNVs with autism and SCZ. We specifically searched
for CNVs for AD+P in the above 7 CNV regions previously
reported to be shared across autism and SCZ, using the Illumina
HumanOmni1-Quad BeadChip (San Diego, CA, USA).
Materials and Methods
Subjects
AD cases and controls were recruited through the University of
Pittsburgh Alzheimer’s Disease Research Center. Controls met the
criteria for being free of dementia using the Mini Mental State
Exam. Cases were those with diagnosis of either probable or
definite AD according to criteria set by the National Institute of
Neurological and Communicative Disorders and Stroke –
Alzheimer’s disease and Related Disorders Association [14] and
the Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD). All cases have age of onset of at least 60 years. Subjects
with evidence of persistent and or recurrent delusions or
hallucinations, defined by the CERAD behavior rating scale
[15] items for psychotic features (items 33–35) rated as occurring
three or more times in the past month at any visit, were classified
as AD+P, as previously described [16] Subjects with evidence of
infrequent distortions of thought or perception, defined by any of
these items rated as occurring 1 to 2 times in the past month, were
classified as "indeterminate psychosis’’ as such symptoms can
result from a variety of sources of phenocopies. Subjects rated as
no occurrence of possible psychotic symptoms at all visits were
classified as AD-P. Subjects were excluded if they had a previous
history of SCZ or bipolar disorder. The University of Pittsburgh
ADRC follows a standard evaluation protocol, including medical
history, general medical and neurological examinations, psychiat-
ric interview, neuropsychological testing and MRI scan. All
subjects were recruited with written informed consent, and the
study was approved by the University of Pittsburgh Institutional
Review Board.
Genotyping
All subjects were genotyped using the Illumina HumanOmni1-
Quad BeadChip. Table 1 summarizes the number of individuals
in different categories. After quality control, 2024 samples were
retained for the final analysis. Details on the study population
characteristics and the quality control parameters applied on the
samples and markers can be found elsewhere [17,18]. Briefly,
samples were filtered if they had a missing genotype rate$0.02, or
with mean X-chromosome heterozygosity $0.02 for males or
outside the range of 0.25,0.4 for females. Genetic outliers and
those with evidence of relatedness (IBD estimate $0.4) or non-
European ancestry based on genotype data were also excluded.
After filtering, 496 AD+P cases, 639 AD intermediate P, 156 AD2
P cases and 958 unaffected controls were retained. Markers were
excluded if they had a genotype missing rate of .0.02. Markers
were examined to determine if missing depended on case/control
status or the genotyping batch.
Detection of CNVs
We generated CNV calls using the PennCNV software (2009
Aug27 version) [19]. PennCNV is a Hidden Markov Model
(HMM) based method. It uses the log R ratio (LRR) and B allele
frequency (BAF) measures computed from the signal intensity files
by Beadstudio to detect the CNVs. We used the GC model wave
adjustment procedure in PennCNV. After GC model adjustment,
we filtered the samples that met the criterion of LRR standard
deviation $0.3, and |GC base pair wave factor (GCWF)| .0.05
(Table 1). All procedures followed the user guidelines of
PennCNV. PennCNV inferred the copy number at each marker,
and called a CNV when copy number changes in 3 or more
consecutive markers. CNVs with copy number.2 were defined as
duplications; while those with copy number ,2 were considered
deletions. We specifically searched for rare CNVs in the 7
recurrent CNV regions identified across autism spectrum disorders
(ASD) and SCZ and summarized by Moreno-De-Luca et al [13].
We plotted the number of individuals who carried CNVs in those
7 regions by different sub-groups (AD+P, AD indeterminate P,
AD- P, and no-AD). We also drew the LRR and BAF plots for
each of the identified CNV carriers. The significance of association
between CNVs and AD+P was measured by Fisher’s exact test. All
data analysis was programmed in R (2.15.2) [20], except for power
analysis which was completed using G*Power (3.0.10) [21].
Human NCBI Build 36 (hg18) was used for this study.
Verification of predicted CNVs
We validated our CNV findings using the NanoString nCounter
CNV Custom CodeSets (Seattle, WA, USA) and following the
manufacturer’s protocol (Genomics and Proteomics Core Labo-
ratories, University of Pittsburgh). We tested 46 samples in the
validation study: two AD+P subjects with predicted 16p11.2
duplication CNV; six AD+P subjects without CNVs; three AD
subjects with indeterminate psychosis; one AD-P subject; and 34
non-AD individuals. In addition, two replicates were included in
the analysis in order to test the consistency of our findings. A total
of 10 CNV probe pairs were designed targeting the region of
interest on chromosome 16 (from 29,554,843 bp to
30,105,652 bp). Briefly, Genomic DNAs were fragmented into
small pieces (200–800 bp) and denatured to produce single
strands. The fragmented, denatured DNA samples were then
hybridized to the Custom CNV CodeSets, each containing a
capture probe and a reporter probe tagged with a fluorescent
barcode. Hybridized DNA-CodeSet complexes were then aligned
and immobilized in the nCounter Cartridges, which were
transferred in the nCounter Digital Analyzer for data collection.
We first assayed quality control checks on the raw code count data
and then normalized them to a set of control probes representing
invariant genomic regions. For each probe, the copy number was
determined by calculating the ratio of normalized counts from a
test sample to the counts of reference samples comprising a pool of
34 non-AD controls in this study. The ratio of counts was then
rounded to the nearest integer to generate the final copy number
calls. All the calculations were done using the R statistical analysis
software (version 2.15.2) [20].
Results
We detected a large (.0.5 Mb) and rare duplication CNV (copy
number = 3) on chromosome 16p11.2. It was present in 2 of 440
AD+P subjects but in none of 593 AD subjects with indeterminate
psychosis, of 136 AD-P subjects, and of 855 non-AD controls
(Table 2). The LRR and BAF plots of 16p11.2 duplication in two
AD+P cases were shown in figure 1. The primary significance of
this finding is that this large duplication of known pathogenicity is
found at all in the individuals with AD+P. Statistical significance is
highly dependent on the precise hypothesis being tested. Based on
Fisher’s exact test, the p-value for a difference between the
frequency in AD+P subjects and AD-P subjects is 1.0. The p–value
16p11.2 Duplication in AD+P
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for the difference between AD+P and all other AD subjects is 0.14.
The p-value for the difference between AD+P subjects and all
other subjects (including non-AD) is 0.047. Each of these tests
implies a different model for this duplication as a risk factor. It is
not possible at the current sample size to say which of these models
best fits the data. When type I error a is set at 0.05, our power to
identify CNVs with frequency #0.5% in 440 AD+P subjects
compared to 0% in all 1584 non-AD+P subjects is 65%. The
power dropped to 18% to detect the same difference between 440
AD+P patients and all 729 other AD subjects, which may explain
the borderline significant difference on 16p11.2 in the comparison
of these two groups.
This duplication CNV almost completely overlaps with the
previously reported 16p11.2 CNV region in autism and SCZ,
spanning from 29,557,553 to 30,107,434 bp in SCZ and autism
and from 29,554,843 to 30,105,652 bp in our study. The
frequency of this duplication CNV in AD+P individuals (Table 2)
is comparable to that reported in the combined samples from
Shane’s two large SCZ studies [22]. In the combined SCZ sample,
21 of 4551 cases (0.46%) carried this duplication compared with 2
of 440 AD+P cases in our study (0.46%).
The presence of the duplication was validated using the
NanoString CNV Custom CodeSets (10 probe pairs). Table 3
lists the actual decimal copy number estimates generated by the
ratio of counts from test samples to reference samples (34 non-AD
individuals) and the final rounded integer copy number in two
AD+P subjects with 16p11.2 duplication predicted by PennCNV
as compared to random subjects without predicted CNVs. As
expected, the final CNV calls for each of the 10 probes were 3 in
duplication CNV carriers as compared to 2 in all other subjects,
completely validating our findings.
We did not find any CNVs greater than 50 Kb in the other 6
CNV regions that we investigated. We also did not find any
deletions in the 16p11.2 region. Deletions in this region have been
associated with mild mental retardation, autism, and other non-
behavioral phenotypes [23–25].
Discussion
To our knowledge, we are the first to report that patients with
AD+P share a rare risk CNV on chromosome 16p11.2 with SCZ
and autism patients. The frequency of the duplication in our AD+
P cohort is 0.46% (2 out of 440 AD+P), which is similar to that
previously reported in SCZ. This frequency estimate is very
approximate due to the small sample size; however, a larger
replication cohort is warranted for further investigation.
Several discrete phenotypes, such as developmental delay,
intellectual disability, behavioral problems, autism, schizophrenia,
and bipolar disorder have been previously shown to be associated
with the microduplication of 16p11.2 and are considered as
16p11.2 duplication syndromes [22,24–27]. Further, a newly
published paper [28] revealed a common variant (rs4583255)
located at 16p11.2 that increased the risk of both SCZ and bipolar
disorder with similar odds ratios. Since the 16p11.2 duplication
has been previously reported in the above psychiatric disorders, we
examined whether comorbidity existed in these two AD+P
patients. Medical history and examination showed these two
AD+P patients had no personal history of, nor any identified
family history of, SCZ, bipolar disorder and autism.
Our finding potentially extends the range of 16p11.2 duplica-
tion syndromes to psychosis in Alzheimer’s disease. Pleiotropy of
CNVs has been established [29], however, the genetic etiology of
the pleiotropic effects is unknown. It has been proposed by
DeMichele-Sweet and Sweet [30] that neurodevelopmental
disorders and neurodegenerative disorders (e.g., AD) may share
some common disease modifier genes, which may be involved in
the development of psychosis in different disorder processes. Our
findings partially support one of their hypothesized pathways. It is
possible that distinct psychiatric disorders share the same or
similar genetic factors affecting the same or neighboring (and
maybe functionally-related and/or interacting) genes, perhaps
influenced by different genetic and/or environmental modifiers.
The quite different disease onset time between patients with AD+P
and some patients with neurodevelopmental disorders, such as
Table 1. Sample sizes for each study group before and after filtering by LRR (Log R Ratio) deviation.
AD+P AD intermediate P AD-P Non-AD controls
Before filtering 496 639 156 958
After filtering 440 593 136 855
AD: Alzheimer’s disease; AD+P: subjects with psychosis in Alzheimer’s disease; AD-P: subjects with Alzheimer’s disease without psychosis.
doi:10.1371/journal.pone.0111462.t001
Table 2. Comparison of the duplication CNV on 16p11.2 identified in AD+P in this study to that reported in SCZ (McCarthy et al.’s,
2010).
CNV Position Number of total subjects Number of subjects with CNV Frequency of CNV
AD+P 29,554,843–30,105,652 440 2 0.0046
AD intermediate P 593 0 0
AD-P 136 0 0
No-AD controls 855 0 0
SCZ 29,557,498–30,107,355 4551 21 0.0046
No-SCZ controls 6391 2 0.0003
AD: Alzheimer’s disease; AD+P: subjects with psychosis in Alzheimer’s disease; AD-P: subjects with Alzheimer’s disease without psychosis. SCZ: schizophrenia.
doi:10.1371/journal.pone.0111462.t002
16p11.2 Duplication in AD+P
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autism, may be partially related with incomplete but substantial
(,30–50%) penetrance of 16p11.2 duplication [22] or genetic
mosaicism of the 16p11.2 region [31].
Microduplication of 16p11.2 lies in a chromosomal rearrange-
ment hotspot [31] and dosage-sensitive loci [32], which contain
about 25 genes (SPN, QPRT, JCLN, KIF22, MAZ, PRRT2,
MVP, CDIPT, PIS, SEZ6L2, ASPHD1, KCTD13, FKSG86,
TMEM219, TAOK2, HIRIP3, INO80E, DOC2A, ALDOA,
PPP4C, TBX6, YPEL3, GDPD3, MAPK3, and CORO1A). Most
of these 25 genes are expressed in brain, among them several genes
have been found to be involved in Alzheimer’s disease, including
SPN (sialophorin, also named as CD43), CORO1A (coronin, actin
binding protein, 1A), QPRT (quinolinate phosphoribosyltransfer-
Figure 1. LRR and BAF plots for 16p11.2 duplication in two AD+P cases. LRR and BAF values for each probe are represented as dots. The
black arrow delineates the position of the duplication (chr16: 29,557,553 to 30,107,434 bp). LRR values for the SNP and copy-number probes in the
duplication increase and BAF values for the SNP probes cluster randomly around 0, 1/3, 2/3 and 1. In comparison, the flanking normal chromosomal
regions have LRR values centered around zero with three BAF clusters (0, 1/2 and 1).
doi:10.1371/journal.pone.0111462.g001
16p11.2 Duplication in AD+P
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ase), MAZ (MYC-associated zinc finger protein), and MAPK3
(mitogen-activated protein kinase 3, also named as ERK1).
Expression change of SPN in human microglia was reported in
Alzheimer’s disease [33]; Specific carbonyl level of CORO1A was
reduced during the treatment to reduce Amyloid b-peptide levels
in mouse model [34]. QPRT is the enzyme responsible for
quinolinic acid (QUIN) turnover in the kynurenine pathway of
tryptophan degradation. Increased QUIN has been reported in
AD brain [35]. Increased concentrations of kynurenine pathway
metabolites have also been reported for disorders involving
psychosis, including schizophrenia and bipolar disorder [36].
ZF87/MAZ and FAC1 co-localize to pathologic structures in
Alzheimer’s disease brain. The interaction of these two proteins
was involved in gene regulation in neurodegeneration [37,38].
MAZ was also identified as a blood biomarker in schizophrenia
[39]. Accumulated evidence have shown that up-regulation of
MAPK3 (ERK1) are associated with the progression of Alzhei-
mer’s disease [40–44]. In addition, expression of MAPK3 is
significantly associated with a locus (rs4583255[T]) on 16p11.2
which shows genome-wide significant association with psychosis,
including schizophrenia, bipolar disorder and related psychoses by
a recent GWAS (genome-wide association study) in a large cohort
[45]. It also modifies the effect of KCTD13 on zebrafish head size
[32].
KCTD13 (potassium channel tetramerization domain contain-
ing 13) was revealed recently by Golzio et al [32] as a major driver
for the neurodevelopmental phenotypes associated with the
16p11.2 CNV, and 16p11.2 duplication was associated with
microcephaly phenotype in zebrafish embryos with MAPK3 and
MVP named as possible modifiers. They further reported that
microcephaly was caused by decreased proliferation of neuronal
progenitors with concomitant increase in apoptosis in the
developing brain by zebrafish and mouse embryos. This may
explain a common effect for these three distinct phenotypes.
However, we cannot exclude the possibility that the genes
contributing to psychosis in AD are different from the genetic
effects leading to any of the other disorders. It is also unknown if
this CNV plays a heterogenetic role in the development of AD and
subsequent psychosis or it modifies risk of psychotic symptoms in
the presence of AD pathology. Given the low frequencies of the
duplication, it may not be possible to discern these two
possibilities.
Although we validated this 16p11.2 duplication using the
NanoString technology, future studies are warranted to replicate
our findings in large independent samples. Also, since this
duplication is about 550kb long and contains about 25 genes,
and its effect on functionality of those 25 genes is unclear, more
work is necessary to further refine this important region and to
identify the disease causing gene(s). The Simons VIP Consortium
[46] has recently launched a project to study the genetic causes of
neuropsychiatric disorders with primary focus on the 16p11.2.
It should be noted that even though the 16p11.2 duplication
may play an important role in development of psychosis of
Alzheimer’s disease, as in autism and schizophrenia, its frequency
is low (0.46%) compared to the disease frequency (40,60% of AD
patients who develop psychosis), which suggests that 16p11.2
duplication can be responsible only for a small fraction of
psychiatric morbidity. A potential limitation of this study is that
it has restricted power to detect very rare CNVs in AD+P. We
consider our study primarily as a case report; the estimation of
frequency, p-value and/or power will require larger cohorts.
Besides those 7 CNV regions previously reported to be shared
across autism and SCZ, a newly published paper [47] identified a
duplication overlapping the p21 Protein-Activated Kinase (PAK7)
as a risk factor for psychosis. We did not find duplications/
deletions overlapping this gene in our study.
In conclusion, although rare, the 16p11.2 duplication we have
identified in AD+P may help to understand an underlying
mechanism for the development of psychosis in AD. In addition,
this CNV has the potential to be used in clinical practice for
screening, diagnosis, and classification of psychosis in AD.
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